Trial · NCT02165397
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 | Ibrutinib + Rituximab | 68.0 | 95% Confidence Interval 54.8 to 78.1 | percentage of participants | |
| Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 | Placebo + Rituximab | 25.3 | 95% Confidence Interval 15.3 to 36.6 | percentage of participants | |
| Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 | Open-Label Substudy: Ibrutinib | 39.7 | 95% Confidence Interval 22.3 to 56.7 | percentage of participants | |
| Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized | Ibrutinib + Rituximab | 76.0 | percentage of participants | ||
| Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized | Placebo + Rituximab | 30.7 | percentage of participants | ||
| Overall Response Rate (ORR) Based on IRC Assessment Up to 3 Years After Last Participant Randomized | Open-Label Substudy: Ibrutinib | 77.4 | percentage of participants | ||
| Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment. | Ibrutinib + Rituximab | 87.4 | 95% Confidence Interval 77.2 to 93.3 | percentage of participants | |
| Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment. | Placebo + Rituximab | 29.4 | 95% Confidence Interval 18.2 to 41.6 | percentage of participants | |
| Time to Next Treatment (TnT) Time From the Date of Randomization to the Start Date of Any Subsequent WM Treatment. | Open-Label Substudy: Ibrutinib | 64.6 | 95% Confidence Interval 44.1 to 79.2 | percentage of participants | |
| Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized | Ibrutinib + Rituximab | 77.3 | percentage of participants | ||
| Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized | Placebo + Rituximab | 42.7 | percentage of participants | ||
| Percentage of Participants With Sustained Hemoglobin (Hgb) Improvement Up to 3 Years After Last Participant Randomized | Open-Label Substudy: Ibrutinib | 71.0 | percentage of participants | ||
| Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score | Ibrutinib + Rituximab | 68.0 | percentage of participants | ||
| Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score | Placebo + Rituximab | 54.7 | percentage of participants | ||
| Percentage of Participants With ≥ 3 Points Increase From Baseline by Week 25 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Subscale Score | Open-Label Substudy: Ibrutinib | 87.1 | percentage of participants | ||
| Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54 | Ibrutinib + Rituximab | 86.4 | 95% Confidence Interval 73.7 to 93.3 | percentage of participants | |
| Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54 | Placebo + Rituximab | 84.2 | 95% Confidence Interval 71.3 to 91.6 | percentage of participants | |
| Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 54 | Open-Label Substudy: Ibrutinib | 73.4 | 95% Confidence Interval 53.7 to 85.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02165397/results